A Phase 1 Study of AZD9592 Alone and With Other Treatments in People With Solid Tumors


Full Title

A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors


Researchers want to find the best dose of AZD9592 to use in people with lung and head and neck cancers. They will assess AZD9592 when it is given alone and with the anti-cancer drug osimertinib. The people in this study have advanced non-small cell lung cancer (NSCLC) or head and neck cancer with mutations (changes or variants) in the EGFR gene.

If you join this study, you will get AZD9592 alone or with osimertinib. AZD9592 is given intravenously (by vein) and osimertinib is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have NSCLC or squamous cell head and neck cancer that has grown beyond its original location or metastasized (spread).
  • Have completed prior chemotherapy at least 3 weeks before getting the study treatment. Any radiation therapy or immunotherapy must have finished at least 4 weeks before.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Helena Yu’s office at 646-608-3912.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID